Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.

Molecular medicine (Cambridge, Mass.) - 5 Nov 2024

Xu Chungui, Lin Weihao, Zhang Qi, Ma Yarui, Wang Xue, Guo Ai, Zhu Guiling, Zhou Zhendiao, Song Weiwei, Zhao Ziyi, Jiao Yuchen, Wang Xiaobing, Du Chunxia

Abstract excerpt

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with a low 5-year survival rate. Treatment options for PDAC patients are limited. Recent studies have shown promising results with MRTX1133, a KRASG12D inhibitor that demonstrated potent antitumor activity in various types of tumors with KRASG12D mutation. Resistance to KRAS inhibitors is frequently occurred and one of the main reasons...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Ferroptosis

Share to Mice, Nude

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39501138
DOI: 10.1186/s10020-024-00972-y
PMCID: PMC11536589

Genes

MGST1
KRAS
CTNNB1
TCF4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MGST1 facilitates novel KRASG12D inhibitor resistance in KRASG12D-mutated pancreatic ductal adenocarcinoma by inhibiting ferroptosis.PMID 39501138Read ↗

Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.Semantic proximity Read ↗

Alpha-Heredin targets CAMKⅡ/DRP1-Mediated mitochondrial fission to trigger ferroptosis in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Dual Inhibition of KRAS G12D and PI3K/BRD4 signaling overcomes therapeutic resistance in pancreatic cancer.Semantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity Read ↗

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine-Resistance in Pancreatic CancerSemantic proximity Read ↗

Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS proteinSemantic proximity Read ↗

Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?Semantic proximity Read ↗

TMEM87A/EBP/7-DHC/7-DHD Axis Promotes Pancreatic Cancer Progression via Ferroptosis EvasionSemantic proximity Read ↗

Targeting CRABP-II Overcomes Pancreatic Cancer Drug Resistance By Reversing Lipid Raft Cholesterol Accumulation and AKT Survival SignalingSemantic proximity Read ↗

Repurposing DPP-4 inhibitors as anticancer agents in KRAS-mutated pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.